Fifth edition Alnoor Bhimani Charles T. Horngren Srikant M. Datar Madhav V. Rajan Farah Ahamed



Download 1.72 Mb.
View original pdf
Page146/469
Date01.12.2021
Size1.72 Mb.
#57828
1   ...   142   143   144   145   146   147   148   149   ...   469
solutions-manual-to-bhimani-et-al-management-and-cost-accounting-pearson-2012-1
Preferred options
Sell
Altox at split-off

€595,000 Sell
Lorex at split-off
1,125,000 Process Hycol further


667,500

2,387,500 Joint costs
1,800,000 Operating income

€587,500
Nor-Pharma is €32,500 better off by changing two of its current policies – it should sell Lorex at split-off (€25,000 improvement) and process Hycol further (€7,500 improvement.
3 ab Nor-Pharma would be better off by €12,000 by selling Dorzine to Nor-Chem. Further processing Dorzine Incremental revenue
(€0.75
× 50,000) + a €55,000
€37,500 + €17,500 Incremental processing cost

43,000 Incremental operating income
€12,000 a Disposal costs avoided by processing further €0.35
× 50,000 = €17,500
b
The decision to treat Dorzine should not affect decisions as to whether to process further or sell at the split-off point. Accounting decisions about joint- product/by-product distinctions do not affect total revenues or total costs.


98
© Pearson Education Limited 2012

Download 1.72 Mb.

Share with your friends:
1   ...   142   143   144   145   146   147   148   149   ...   469




The database is protected by copyright ©ininet.org 2024
send message

    Main page